非小细胞肺癌靶向治疗研究进展

Research progress of target therapy in non- small cell lung cancer

研究发现非小细胞肺癌与多种致癌突变密切相关,如表皮生长因子受体突变、间变性淋巴瘤激酶重排以及肝细胞生长因子受体扩增等。本文从腺癌和鳞状细胞癌两个亚型入手,分别介绍了非小细胞肺癌潜在的分子靶点及其抑制剂,包括EGFR抑制剂、ALK抑制剂、ROS1抑制剂、c-MET抑制剂、RAS抑制剂、BRAF抑制剂、HER-2抑制剂、NTRK1抑制剂、RET抑制剂、MEK1抑制剂、PI3K抑制剂、FGFR1抑制剂、DDR2抑制剂及IGF-1R抑制剂。为非小细胞肺癌患者临床用药和靶向治疗药物开发提供参考。

With the continuous development of molecular biology,people have gained a deeper understanding of non- small cell lung cancer( NSCLC). Researchers have found that multiple oncogenic driver mutations are closely associated with the development,progression and prognosis of NSCLC,such as EGFR mutations,ALK rearrangement,c-MET amplification. In this review,we choose targeted therapy drugs of ADC and SCC as an entry point to introduce several potential targets and small molecule inhibitors for the treatment of NSCLC,including EGFR inhibitors,ALK inhibitors,ROS1 inhibitors,c- MET inhibitors,RAS inhibitors,BRAF inhibitors,HER- 2 inhibitors,NTRK1 inhibitors,RET inhibitors,MEK1 inhibitors,PI3 K inhibitors,FGFR1 inhibitors,DDR2 inhibitors and IGF- 1R inhibitors.This review will be a helpful guide to clinicians and researchers alike by assisting in therapy decision,making and acting as a platform for further study.